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Parkinson's disease (PD) is known to be a chronic and progressive neurodegenerative disease caused by a selective degeneration of
dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNc). A large body of experimental evidence indicates that the factors
involved in the pathogenesis of this disease are several, occurring inside and outside the DAergic neuron. Recently, the role of the neuron–glia
interaction and the inflammatory process, in particular, has been the object of intense study by the research community. It seems to represent a new
therapeutic approach opportunity for this neurological disorder. Indeed, it has been demonstrated that the cyclooxygenase type 2 (COX-2) is up-
regulated in SNc DAergic neurons in both PD patients and animal models of PD and, furthermore, non-steroidal anti-inflammatory drugs
(NSAIDs) pre-treatment protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6 hydroxydopamine (6-OHDA)-induced nigro-
striatal dopamine degeneration. Moreover, recent epidemiological studies have revealed that the risk of developing PD is reduced in humans who
make therapeutical use of NSAIDs. Consequently, it is hypothesized that they might delay or prevent the onset of PD. However, whether or not
these common drugs may also be of benefit to those individuals who already have Parkinson's disease has not as yet been shown.
In this paper, evidence relating to the protective effects of aspirin or other NSAIDs on DAergic neurons in animal models of Parkinson's
disease will be discussed. In addition, the pharmacological mechanisms by which these molecules can exert their neuroprotective effects will be
reviewed. Finally, epidemiological data exploring the effectiveness of NSAIDs in the prevention of PD and their possible use as adjuvants in the
therapy of this neurodegenerative disease will also be examined.
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Table 1
Evidence of inflammation in PD-Human data
Study Evidence from PD patients
McGeer et al., 1988 Up-regulation of MHC molecules in brains
Mogi et al., 1994a,b Increased level TNF-α, in the striatum and CSF
Mogi et al., 1995 Increased levels of β2-microglobulin, the light chain
of MHC, in striata
Blum-Degen et al.,
1995
Increased levels of IL-1β and IL-6 in the CSF
Rowe et al., 1998 Presence of antibody reactivity to quinone-modified
proteins
Langston et al., 1999 Presence of gliosis and clustering of microglia
around nerve cells in MPTP-induced parkinsonism
in humans
Mirza et al., 2000 Absence of reactive astrocytosis in the inflammatory
process in PD autopsies.
Knott et al., 2000 Up-regulation of nitric oxide synthase- and cyclo-
oxygenase-1- and -2-containing amoeboid microglia
Knott et al., 2002 Up-regulation of glial neurotrophins (BDNF, NT-3) in
response to signals released from failing nigral neurons.
McGeer et al., 2002 Association of interleukin-1 beta polymorphisms with
idiopathic PD
Imamura et al., 2003 The number of activated microglia is higher not only
in the SN and putamen but also in the hippocampus,
transentorhinal cortex, cingulate cortex and temporal
cortex in PD.
Ouchi et al., 2005 Parallel changes in microglial activation and
corresponding dopaminergic terminal loss in the
affected nigrostriatal pathway in early PD.
Ishida et al., 2006 Increased expression of PAR-1 in astrocytes in SNpc
of PD brain.
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Parkinson's disease (PD) is the most prevalent neurological
disorder of the basal ganglia, and it is characterized by a
progressive loss of dopaminergic (DAergic) neurons in the
caudate nucleus, putamen and substantia nigra (SN) (Ehringer
and Hornykiewicz, 1960; Riederer and Wuketich, 1976). The
loss of DAergic neurons in the substantia nigra pars compacta
(SNc) is the principal feature of PD (Bernheimer et al., 1973)
and results in cardinal motor symptoms such as tremor at rest,
bradykinesia, muscular rigidity, stooped posture and instability
(Sian et al., 1999). Hitherto, despite the recent progress in
understanding the etiopathogenesis of PD, the modalities
whereby the neurodegenerative process begins and progresses
are still unclear. The situation is further complicated by the large
number of factors that seem to be involved in the onset of this
disease, such as aging, genetic vulnerability, exogenous or
endogenous toxins, hydroxyl radicals production, neuronal
metabolic disturbances and inflammation (Hirsch et al., 1998;
Sian et al., 1999; Jellinger, 2000; Gebicke-Haerter, 2001; Jenner
and Warren, 2006). The consequent cumulative neuronal insults
attributable to these metabolic stress factors may promote
premature SNc DAergic degeneration through the activation of
apoptotic programs (Hartmann and Hirsch, 2001; Novikova et
al., 2006; Nair et al., 2006). However, the specifics and
sequential neuroapoptotic events associated with premature,
progressive SNc neuronal atrophy remain undefined.
Thus far, among the various accepted experimental models of
PD, neurotoxins still represent the most popular tools to produce
selective death of DAergic neurons both in in vitro and in vivo
systems. Even though recent genetic discoveries have lead to a
number of different genetic models of PD, none of these shows
the typical degeneration of DAergic neurons (Beal, 2001;
Fleming et al., 2005). Among the neurotoxins, 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), a product of syn-
thetic meperidine derivative, and 6-hydroxydopamine (6-
OHDA), hydroxylated dopamine derivatives are the most used
for inducing parkinsonian features in cells and animal species.
MPTP is metabolized to the 1-methyl-4-phenylpyridinium ion
(MPP+) by monoamine oxidase-B (MAO-B) (Langston et al.,
1984). This highly toxic metabolite is selectively taken up into
DAergic neurons, via the dopamine (DA) transporter (Snyder
and D'Amato, 1986), where it provokes an intracellular
accumulation of Ca2+, interfering with the function of nerve
terminals in the striatum (Sun et al., 1988) and inhibiting
complex 1 (NADH-ubiquinone oxidoreductase) of the respira-
tory chain causing progressive cell death (Cleeter et al., 1992).
On the other hand, the neurotoxic effects of 6-OHDA are
mediated by the generation of hydroxyl radicals, pro-inflamma-
tory mediators or pro-apoptotic agents (Cohen, 1984; Jeon et al.,
1995; Bové et al., 2005). The results of the administration of
each neurotoxin, albeit by different mechanisms, is DA
depletion in the nigro-striatal pathway of laboratory animals
and molecular alterations comparable to those seen in PD's
patients (Blum et al., 2001). Recently, it has been shown that
6-OHDA and MPTP like the bacterial lipopolysaccharide (LPS)
induce the death of DA cells activating an immune response(Wang et al., 2005; Vijitruth et al., 2006; de Meira Santos Lima
et al., 2006). These animal models have been crucial in the study
of PD and have allowed the formulation of different hypotheses
about its etiopathogenesis, and recently, they have been utilized
to determine the role of inflammation in DA neuronal death.
Moreover, toxin-based models have been useful in developing
neuroprotective and neurorestorative strategies and in testing
new drugs for the treatment of this disorder. In this review,
experimental data regarding the role of neuroinflammation in the
aetiology of PD, the effect of non-steroidal anti-inflammatory
drugs (NSAIDs) and the possibility for their use as a new
therapeutic approach for this neurodegenerative disease will be
reviewed.
Inflammation in Parkinson's disease
Decades of research on the aetiology of Parkinson's disease
have resulted in much information, but little has been gained in
establishing the events causing the initiation and progression of
the disease. Recently, the involvement of neuroinflammation
and microglial activation in the pathogenesis of PD (Table 1)
has been emphasized (Mogi et al., 1994a,b; Mogi et al., 1995;
Blum-Degen et al., 1995; Rowe et al., 1998; Langston et al.,
1999; Mirza et al., 2000; Knott et al., 2000, 2002; McGeer et al.,
2001; McGeer et al., 2002; Imamura et al., 2003; Ouchi et al.,
2005; Ishida et al., 2006; Kim and Joh, 2006). Results of
neurotoxin models of PD, corroborating findings obtained in
transgenic animal models and epidemiological studies, strongly
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purely neuronal, as it has been previously considered (McGeer
and McGeer, 2004; Hald and Lotharius, 2005). DAergic
neuronal degeneration is the likely result of multiple pathogenic
factors occurring both within and outside the cell. The cross-talk
between neurons and glia is becoming more and more important
for the understanding of brain pathophysiology. This new
finding, unfortunately, does not allow us to diagnose the disease
any earlier because the neuroinflammatory process is silent and
unnoticed due to the absence of pain fibres in the brain, but it at
least gives a glint of hope for new potential therapeutic targets
for the slowing of neuronal degeneration.
Neuroinflammation is not a distinctive characteristic of PD
but it has been clearly revealed in a broad spectrum of neuro-
degenerative diseases that share with it a common pathological
process, such as Alzheimer's disease (AD), Huntington's di-
sease (HD), amyotrophic lateral sclerosis (ALS) and multiple
sclerosis (MS) (Minghetti, 2005; Kim and Joh, 2006; Pavese et
al., 2006). The scenario is still obscure, but inflammation in PD
is not any longer considered a non-specific consequence of
neuronal degeneration as it was originally thought to be. Indeed,
neuroinflammation may aggravate the course of the disease and,
as has recently been suggested, may be a primary factor in some
cases of PD (Hald and Lotharius, 2005; Marchetti and Ab-
bracchio, 2005; Kim and Joh, 2006; Jenner and Warren, 2006).
In fact, postmortem examinations have shown that neuronal
degeneration in PD is associated with massive gliosis due to a
population of activated glial cells, the microglia (McGeer et al.,
1988; Członkowska et al., 2002; Teismann et al., 2003),
evidence that has been confirmed inMPTP-induced parkisonism
in monkeys (McGeer et al., 2003) and humans (Langston et al.,
1999). Interestingly, the SN, usually prone to the deleterious
effects of oxidant stress, containing DA neurons high in iron and
low in glutathione (Jenner and Olanow, 1998, 2006), is also one
of the brain regions more sensitive to inflammation. Indeed, the
healthy SN exhibits the highest concentration of microglia in the
brain especially in the ventral tier of the pars compacta (Lawson
et al., 1990; Kim et al., 2000). Normally, very few microglial
cells are detected in the vicinity of DAergic neurons, and when
present, they appear to be resting with fine, long processes.
Neuronal damage, aggregated proteins with abnormal confor-
mations present in Lewy bodies and other unknown factors
increase the number and change the shape of glial cells, to such
an extent that they can be found in proximity to DA cells with
short cellular processes (Zhang et al., 2005). Activated microglia
are recruited to the SNc from various structures and finally stuck
to DA neurons. It has been shown that glial cells once activated
become phagocytes that ingest degenerating DA neurons piece-
by-piece. This occurs early in neuronal degeneration, starting at
the extending fibres, such as the dendrite which extends into the
SN reticulata (Sugama et al., 2003). Hence, activated glial cells
release detrimental compounds such as, interleukin (IL)-1β, IL-
6, tumor necrosis factor-α (TNF-α) and interferon γ (IFN- γ),
which may act by stimulating inducible nitric oxide synthase
(iNOS), or which may exert a more direct deleterious effect on
DAergic neurons by activating receptors that contain intracyto-
plasmic death domains involved in apoptosis (Kataoka et al.,1997; Mogi et al., 1998; Kaku et al., 1999; Kurkowska-
Jastrzębska et al., 1999a,b; Knott et al., 2000; Iravani et al.,
2002; Teismann et al., 2003; Przybyłkowski et al., 2004; de
Meira Santos Lima et al., 2006). Microglia can also induce
neuritic beading (Takeuchi et al., 2005) or synaptic stripping
along dendrites (Schiefer et al., 1999) leading to synaptic
disconnection and loss of trophic support and cell death (Isacson
et al., 1985; Jiang et al., 2006). Given that glial cells are potent
activators in lymphocyte invasion, animal studies using MPTP
have shown that the immune reaction might evolve, ultimately
leading to the infiltration of lymphocytic CD4+ and CD8+ Tcells
into the injured SN and striatum (Kurkowska-Jastrzębska et al.,
1999a,b). Moreover, activated lymphocytes have been shown in
the SN of patients with PD and they could be responsible for the
immune reaction-associated inflammatory process seen in the PD
brain (McGeer et al., 2001; Baba et al., 2005).
Such activation of microglia is, nevertheless, not only dis-
advantageous to neurons. Indeed, some investigations indicate
that activated microglial cells and macrophages tend to synthesise
and produce neurotrophic factors (brain-derived neurotrophic
factor, BDNF and glia-derived neurotrophic factor, GDNF)
through certain compensatory mechanisms following neuronal
injury and induce sprouting surrounding the wound in the striatal
DA terminals (Batchelor et al., 1999; Minghetti et al., 2005).
Moreover, activated glia play a role in gradually removing the
deadDAneurons as a defencemechanism, although some healthy
DA neurons might also be phagocytosed during the process
(Novikova et al., 2006; Cho et al., 2006). As a consequence,
inflammation has been rightly defined as a double-edged sword. It
normally starts as a defence reaction but, for the failure of its
control mechanism, can lead to an uncontrolled and continuous
extremely damaging immune response. Furthermore, brief
pathogenic insult, can induce an ongoing inflammatory response
and the toxic substances released by the glial cells may be
involved in the propagation and perpetuation of neuronal
degeneration. This theory is plausible, corroborated by the
evidence that several years after exposure to MPTP, increased
levels of factors such as, IL-1β, IL-6 and TNF-α have been found
in the basal ganglia and cerebral spinal fluid (CSF) of patientswith
toxin-induced PD (McGeer et al., 2001).
A prominent factor in neuroinflammatory reactions in PD
seems to be the activation of the complement system (Mirza et
al., 2000; Loeffler et al., 2006; Bonifati and Kishore, 2007) a
major mediator of immune/inflammation reactions. Indeed,
increased mRNA levels of complement components have been
found in affected brain regions (McGeer and McGeer, 2004).
The presence of complement components, including all
constituents of the membrane attack complex (MAC), has
been shown intracellularly on Lewy bodies and on oligoden-
droglia in the SN of PD patients (Yamada et al., 1991, 1992,
1993). Accumulation of Lewy bodies can apparently cause the
activation of complement, the initiation of reactive changes in
microglia, and the release of potentially neurotoxic products
such as the MAC, hydroxyl radicals, and excess glutamate
(GLU) (McGeer and McGeer, 1998).
So far, among the plethora of toxic factors released by the
reactive glia it is not clear which one of them is responsible for
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hydroxyl radicals , NO and its peroxinitrite (ONOO−), are the
likely candidates (Di Matteo et al., 2006a,b). From this evidence
it appears clear that the inflammatory process and oxidative
stress derived from DA metabolism, constitute a vicious cycle
that lead to the final demise of nigral DA cells (Fig. 1) (Hald and
Lotharius, 2005).
Furthermore, experimental evidence has also shown that
inflammatory loss of DA nigro-striatal neurons might be
mediated by apoptosis (Cassarino et al., 2000; Lee et al.,
2001; Furuya et al., 2004; Arimoto et al., in press; Ruano et al.,
2006). Indeed, inflammation induced by intranigral injection of
LPS could be mediated, at least in part, by the mitogen-activated
protein kinase p38 (MAPK p38) signal pathway leading to
activation of inducible nitric oxide synthase (iNOS) and
cysteine protease caspase-11 (Ruano et al., 2006). Consistent
with this evidence, it has been recently shown that LPS-induced
inflammation causes apoptosis in the SNc due to increased pro-
inflammatory cytokine levels of mRNA for TNF-α, IL-1α, IL-
1β and IL-6, and the apoptosis-related genes Fas and Bax and
caspase-3 immunoreactivity (Arimoto et al., in press). These
data have also been confirmed in a MPTP mouse model,
neurotoxic effect seems to be mediated via activation of the
caspase-11 cascade and inflammatory cascade, as well as the
mitochondrial apoptotic cascade (Furuya et al., 2004). The link
between apoptotic signalling cascade and inflammation could
follow other pathways. In fact, in a chronic MPTP model of PD,
activation of the nuclear transcription factor NF-κB, that is well
known for its role in preventing apoptotic cell death, has been
revealed (Dehmer et al., 2004). NF-κB, among other effects,
promotes the synthesis of cyclooxygenase types 2 (COX-2)
(Baeuerle and Baichwal, 1997). COX-2 induction, in turn
increases inflammatory response with the formation of different
types of free radicals, a tyrosyl one and two different carbon-Fig. 1. Classical versus non-classical effects of NSAIDs. Abbreviations: COX
Prostaglandin H2; Prostaglandin F2alha, PGF2α; Prostaglandin D2, PGD2; Prostagland
B, NF-κB; Peroxisome proliferator-activated receptor gamma, PPARγ; Inducible nit
regulated kinases, ERKs; P38 mitogen-activated protein kinases, p38 kinases; factocentred free radicals as well (Fig. 1), capable of causing
phospholipid peroxidation (Marnett, 2000; Jiang et al., 2004).
The release of arachidonic acid (AA) also inhibits GLU
uptake contributing to the neurodegenerative processes seen in
PD (Dugan and Choi, 1999). COX-2 could also be induced by
pro-inflammatory cytokines such as TNF-α via the c-Jun N-
terminal kinase (JNK) pathway (Westwick et al., 1994; Adams
et al., 1996; Teismann et al., 2003).
Nonetheless, it is with underlining that the interactions
between apoptotic neurons and microglia don't always have
detrimental effects but they can lead microglia to acquire an
anti-inflammatory phenotype. Indeed, recent studies from
Minghetti's group have provided evidence that under chronic
stimulation the interaction with apoptotic cells contributes to a
progressive down-regulation of glial pro-inflammatory mole-
cule expression and a sustained release of immunoregulatory
substances, such as PGE2 and TGF-β1, while promoting the
synthesis of other products with potential immunoregulatory
and protective activities (De Simone et al., 2004; Minghetti et
al., 2005; Minghetti, 2005).
Old and new mechanisms of action for NSAIDs
The above discussion makes it plausible that drugs with the
capacity to rescue DA neurons from microglia toxicity and
inflammatory processes, may result in an amelioration of
parkinsonian symptoms by delaying the onset and slowing the
progression of the disease (Gao et al., 2003; Marchetti and
Abbracchio, 2005; McCarty, 2006). Several agents have been
shown to inhibit microglial or monocytic cell neurotoxicity
(Klegeris and McGeer, 2005; McCarty, 2006). Among them
much attention has been devoted to NSAIDs since it has been
shown by experimental and clinical observation that they may
represent a possible new therapeutic approach for treating PD.cyclooxygenase; PLA2, phospholipase A2; PGG2, Prostaglandin G2; PGH2,
in I2, PGI2; Prostaglandin E2, PGE2; Thromboxanes, TXs; Nuclear Factor kappa
ric oxide synthase, iNOS; c-Jun N-terminal kinases, JNKs; Extracellular signal-
r activator protein 1, AP-1.
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share many pharmacological properties (and side effects) and
are the main drugs used as analgesics and antipyretics to reduce
the untoward consequences of inflammation. NSAIDs together
with steroidal anti-inflammatory drugs (SAIDs) are capable of
halting eicosanoids synthesis and suspending inflammatory
process progression. SAIDs, which include both cortisone and
its derivatives, inhibit phospholipase A2 (PLA2) blocking both
the production of leukotrienes (LTs) and PGs via the
discontinuance of AA synthesis. Differently, NSAIDs only
inhibit COX activity inducing a diminution of PGs levels,
accompanied by a compensatory increase of LTs levels (Fig. 2).
The NSAIDs can be classified into three groups based on their
COX inhibition ratios (affinity of inhibition for COX-1 or COX-
2) chemical structures or inhibitory kinetics (Taketo, 1998)
(Table 2). Recently, a new class of NSAIDs has been
synthesized named nitric oxide-donating nonsteroidal anti-
inflammatory drugs (NO-NSAIDs), consisting of a traditional
NSAID to which a NO releasing moiety is covalently attached,
these drugs may have an important role in colon cancer
prevention and/or treatment (Rigas and Kashfi, 2004). The main
pharmacological action of these compounds is on the
metabolism of AA, through the inhibition of the enzymes
possessing COX activity (Vane, 1971) but also suppressing the
COX-2 gene expression as well (Shishodia et al., 2004; Wu,
2006) (Fig. 2). Whenever an inflammatory process occurs, there
is a consequent activation of specific enzymes in the cell wall.
Among them, one of the first activated is PLA2 phospholipase
A2 (PLA2 ) that deacylates fatty acids from the 2nd carbon atom
of the triglyceride backbone of membrane phospholipids,
producing AAs and lyso-phospholipids (Furst, 1999; Vane
and Botting, 1996, 2003). AA is subjected to the action of two
families of enzymes: lipoxygenases (LOX) and COX. TheseFig. 2. Interacting synergistic mechanisms involved in dopaminergic death in
Parkinson's disease. The role of the positive feed back (vicious) circle between
neuronal death, neuroinflammation and/or oxidative stress is depicted.
Abbreviations: Dopamine, DA; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,
MPTP; 6 hydroxydopamine, 6-OHDA; Methamphetamine, METH; lipopoly-
saccharide, LPS.enzymes are able to insert oxygen into the molecule of AA in a
specific way. The 5-lipoxygenase (5-LO) subtype catalyzes
oxidation of AA producing a variety of bioregulators such as
LTs, that play important roles in the maintenance of the
homeostasis of the neuronal cells (Christie et al., 1999). COX
enzymes produce five prostanoids: PGE2, PGF2, PGD2, PGI2
(prostacyclin), and thromboxane A2 (TxA2) through the
intermediate PGH2. These prostanoids bind to specific G-
protein-coupled receptors designated EP (for E-prostanoid), FP,
DP, IP, and TP receptors, respectively (Narumiya, 2003; Bos et
al., 2004). LTs are commonly known as vasoconstrictor and
bronchospastic agents whereas PGs play a pivotal role in all the
biochemical mechanisms inducing pain, hyperpyrexia and
classical signs of inflammation, cytoprotective and cytotoxicity
processes.Bergstrom and colleagues (1964) first described PGs
in the brain more than 40 years ago. Since then, numerous
studies have shown that PGs are formed in certain regions of the
brain and in the spinal cord as a response to a variety of stimuli
and in 1976 the enzyme which is key in the synthesis of PGs
from AA, COX, was purified (Hemler et al., 1976). Subsequent
to the cloning of the COX-1 gene, Dan Simmons and colleagues
identified a second gene with COX activity (COX-2) (Xie et al.,
1991). Recently, a third variant of COX has been described,
initially called COX-3 (Diaz et al., 1992; Chandrasekharan et
al., 2002), that might be the target of acetaminophen
(paracetamol) (Chandrasekharan et al., 2002). COX-3 has
been more appropriately renamed COX-1b being a splice
variant of COX-1 which has retained intron-1 during translation
(Chandrasekharan et al., 2002). It has a completely different
amino acid sequence than the known cyclooxygenases and it
does not seem to show cyclooxygenase activity in mice (Kis et
al., 2006) and rats (Snipes et al., 2005), thus it may well be that
COX-1b is not relevant to humans.
The properties of COX-1 are different to those of COX-2. It
was originally thought that the function of constitutive COX-1
was involved in physiological phenomena, such as cytoprotec-
tion of the stomach, platelet aggregation, and kidney functions,
whereas that of COX-2 was involved in various pathologies.
However, recent studies suggest that the inducible isoform
COX-2 also plays an important role in development and
homeostasis (Hinz and Brune, 2002). In the central nervous
system (CNS), COX-2 plays an important role in membrane
excitability, synaptic transmission and participates in memory
consolidation during REM sleep (Cole-Edwards and Bazan,
2005; Chen and Bazan, 2005).
COX-1 and COX-2 are widely and both constitutively
expressed under normal physiological conditions in human
organs (Yasojima et al., 1999), even though only COX-2 is
dramatically up-regulated during inflammatory processes.
Similarly to the other tissues, the two isoforms are distributed
heterogeneously among the brain cells, COX-1 and COX-1b are
detected in microglial cells, while COX-2 is found in neuronal
and glial cells, astrocytes do not express significant COX levels
(Hoozemans et al., 2001; Kis et al., 2003). Normally, COX-2 is
expressed in low levels in nigral DA neurons, but it becomes
up-regulated in both patients and experimental PD models
(Feng et al., 2002, 2003; Teismann et al., 2003; Wang et al.,
Table 2
Biological, pharmacokinetic and chemical subdivision of NSAIDs
Cox-2/Cox-1 ratio Inhibition kinetics Chemical structure
Nonselective COX inhibitors (e.g. ketorolac or
piroxicam, with ratio ≈1);
simple, competitive
(e.g. ibuprofen and Naproxen)
Carboxylic acids
(e.g. Aspirin and Ibuprofen)
Selective COX-1 inhibitors (e.g. Dexketoprofene
and SC 560 with ratio <0.01)
competitive, time-dependent, reversible
(e.g. Indomethacin and DuP 697)
Pyrazoles
(e.g. Phenilbutazone and Kebuzone)
Preferential COX-2 inhibitors (e.g. ibuprofen and
indomethacin, with ratio 15–60)
competitive, time-dependent, irreversible
(e.g. Aspirin and Valeryl salicylate)
Oxicams
(e.g. Piroxicam and Isoxicam)
Selective COX-2 inhibitors (e.g. coxibs, selective
COX-2, with ratio >1000)
Sulphonamides
(e.g. Valdecoxib and Celecoxib)
Methylsulphones (e.g. Rofecoxib and Etoricoxib)
Arylacetic acid (e.g. Lumiracoxib)
300 E. Esposito et al. / Experimental Neurology 205 (2007) 295–3122005; Vijitruth et al., 2006; de Meira Santos Lima et al., 2006;
Tyurina et al., 2006).
COX-2 expression in neurons has been proposed to increase
the vulnerability of neurons to GLU mediated excitotoxicity. In
the CNS, COX-2 expression increases in neurons following
GLU receptor activation (Nogawa et al., 1997, Hewett et al.,
2000; Carlson, 2003) and is thought to contribute to increased
neuronal death. Genetic evidence also indicates that neuronal
expression of COX-2 leads to excitotoxic cell death. Transgenic
mice that overexpress neuronal COX-2 are more susceptible to
excitotoxic cell death (Kelley et al., 1999) and age associated
neuronal loss (Andreasson et al., 2001). This evidence has been
confirmed in rat ischemic hippocampus, where COX-2
expression was substantially and significantly upregulated in
vulnerable CA1 and not in resistant CA3 and dentate granule
cells (Choi et al., 2006). In contrast, COX-2 null (knockout)
mice exhibit less neuronal death following ischemia, challenge
with NMDA (Iadecola et al., 2001), and MPTP (Feng et al.,
2002, 2003; Miller and Hong, 2005; Vijitruth et al., 2006).
Pharmacological and genetic inhibition of COX-2 is capable of
sheltering DA neuronal bodies in the SNc as well as the striatal
TH-stained fibres against toxin effects, suggesting a protection
of the entire nigrostriatal pathway (Vijititruth et al., 2006).
Potential downstream effectors of COX-2 neurotoxicity on SNc
DA neurons are PGE2 and free radicals generated through both
the oxygenase and peroxidase part of the cycle (Marnett, 2000;
Jiang et al., 2004), levels of which have been found to be
enhanced in experimental models and in PD post-mortem
samples (Teismann et al., 2003; Di Matteo et al., 2006a,b;
Tyurina et al., 2006; Vijitruth et al., 2006). PGE2 mediates
COX-2 neurotoxicity essentially through the activation of EP1/
EP3 receptors that disrupt Ca
2+ homeostasis by increasing its
cellular concentration thus causing excitotoxic neuronal death
(Carlson, 2003; Kawano et al., 2006). Conversely, the activation
of the prostanoid EP2/EP4 G-protein-coupled receptors seems
normally to be associated with neuroprotection (Lee et al.,
2004; Echeverria et al., 2005). PGE2 is present in ventral
midbrain neurons and derives primarily from COX-1 (Teismann
et al., 2003). After a few days of neuronal insult, PGE2
concentration almost doubles due to MPTP-induced COX-2 up-
regulation, although more than half still depends on COX-1
activity (Teismann et al., 2003). Microglia-DAergic neurons
interaction is necessary for MPP+-induced COX-2 activation
and PGE2 production (Wang et al., 2005). The toxin firstinduces reactive microgliosis and secretion of its proinflamma-
tory factors, among them PGE2. These will enhance COX-2 DA
neuronal activity and lead to a second wave of neuronal
damage, which in turn, could reinforce the microgliosis process.
The strong correlations found between COX-2 and PGE2 levels,
microglial activation and dopaminergic neurodegeneration
suggest that COX-2 may mediate microglial activation and
may play a key role in amplifying the inflammatory response
and other toxic effects in a vicious circle, which ultimately
exacerbates dopaminergic neuronal loss (Fig. 1) (Sugama et al.,
2003; Teismann et al., 2003; Wang et al., 2005; Vijitruth et al.,
2006).
The detrimental effects have been discussed above, however,
within the brain, PGE2 production, depending on its level, has
also been associated with protective effects on neurons and glial
cells behaving as an anti-inflammatory molecule (Zhang and
Rivest, 2001; Minghetti, 2004). Indeed, in spite of its classic
role as a pro-inflammatory molecule, several recent in vitro
observations indicate that prostaglandin E2 can inhibit micro-
glial activation. At lower (nanomolar) concentrations, PGE2
protects hippocampal and cortical neuronal cultures against
excitotoxic injury or LPS-induced cytotoxicity (Akaike et al.,
1994; Thery et al., 1994; Kim et al., 2002; McCullough et al.,
2004). The protective effect of EP2 receptor activity has been
confirmed in vivo, in a model of transient forebrain ischemia, in
which the genetic deletion of this PGE2 receptor exacerbates the
extent of neuronal damage (McCullough et al., 2004). PGE2 has
also been shown to down-regulate microglial activation and
expression of pro-inflammatory genes, including TNF-α, both
in vitro and in vivo (Levi et al., 1998; Zhang and Rivest,
2001). Minghetti's group found that the interaction of
microglial cells with apoptotic neurons promotes the synthesis
of PGE2 along with neuroprotective and immunoregulatory
molecules such as TGF-β and NGF (De Simone et al., 2003,
2004). In addition, they have recently given further evidence for
the anti-inflammatory PGE2 effect, showing that it is involved
in the brain cholinergic anti-inflammatory pathway. In fact, glial
α7 nicotinic receptor stimulation reduces the LPS-induced
release of TNF-α and enhances the expression of COX-2 and
the synthesis of PGE2 (De Simone et al., 2005).
COX-2 activation, moreover, might result in direct DAergic
cell demise by producing the neurotoxic oxidant species DA-
quinone (Teismann et al., 2003; Asanuma and Miyazaki, 2006),
and by increasing DNA damage inducing the formation of
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mediated lipid peroxidation (Lee et al., 2005; Williams et al.,
2006).
Aspirin (acetylsalicylic acid, ASA) is the most frequently
used drug in the world to treat inflammation and pain. Aspirin is
the progenitor of the NSAIDs family, it is known to
preferentially inhibit COX-1 rather than COX-2 in an
irreversible way, by acetylating the active site of these enzymes,
producing salicylic acid (SA) (Vane and Botting, 1987, 2003).
Although many of ASA's and other NSAIDs' pharmacological
actions are related to the ability to inhibit prostaglandin
biosynthesis, some of their beneficial therapeutic effects are
not completely understood. NSAIDs are able to inactivate the
transcription factors NF-κB and factor activator protein-1 (AP-
1) which is critical for the induction of neoplastic transforma-
tion and the induction of multiple genes involved in inflamma-
tion and infection (Vane and Botting, 1987; Weissmann, 1991;
Kopp and Ghosh, 1994; Grilli et al., 1996; Dong et al., 1997;
Mitchell et al., 1997; Amann et al., 2001). Diverse noxious
cellular stimuli free NF-κB from any endogenous inhibitor,
permitting the translocation of free NF-κB from the cytoplasm
to the nucleus. Consequently, NF-κB binds to DNA and
activates a number of genes involved in the inflammatory and
immune responses. Some of these gene products, such as TNF
could exert cytotoxic effects by switching on apoptotic self-
destruct programs (Wright et al., 1992; Vaux and Strasser,
1996). ASA and COX-2 selective inhibitors exert antitumor
effects partly through blocking AP-1 activation. AP-1, consist-
ing of Jun/Fos dimers, is a downstream target of MAP kinase
family members including extra-cellular signal regulated
kinases (ERK-1 and -2; p42/p44 MAPK), Jun kinases (JNK),
and p38 MAPK. NSAIDs suppress AP-1 activation through
different mechanisms blocking the activation of ERK and JNK
as well as P38 mitogen-activated protein kinase (p38 kinase)
(Dong et al., 1997; Wong et al., 2004). Furthermore, ASA and
salicylate at therapeutic concentrations inhibit COX-2 protein
expression pointing towards a possible (cell-specific) target of
NSAIDs upstream to COX-2 enzyme activity through inter-
ference with the binding of CCAAT/enhancer binding protein
beta (C/EBPbeta) to its cognate site on COX-2 promoter/
enhancer. Expression of other genes, such as iNOS and
interleukin-4, may be inhibited by ASA and salicylate through
a C/EBP-dependent mechanism or inhibiting NF-κB activation
(Xu et al., 1999; Wu, 2003; Wu, 2006).
Among the COX independent actions, it has been shown that
NSAIDs in neuronal cells, might directly and dose-dependently
scavenge ROS and reactive nitrogen species (RNS) blocking
their detrimental effects (Grilli et al., 1996; Asanuma et al.,
2001). Besides this, the agonistic activity shown at high con-
centration by some NSAIDs such as ibuprofen and indometha-
cin toward the peroxisome proliferator-activated receptor-γ
(PPARγ) seems relevant to neuroprotection (Lehmann et al.,
1997). This receptor PPARγ is a ligand-activated inhibitory
transcription factor that antagonizes the activity of NF-κB,AP-1,
signal transducer and activator of transcription-1 (STAT-1) and
nuclear factor of activated T cells (NFAT) (Lemberger et al.,
1996; Jiang et al., 1998). Its cellular activation is associatedwith a reduction in the expression of several inflammatory
genes (Ricote et al., 1998) and the production of inflammatory
cytokines (i.e., IL-1, IL-6, TNF) (Jiang et al., 1998). In vitro
studies have shown that the selective agonists pioglitazone,
indomethacin and ibuprofen can activate PPARγ in microglia,
reducing the Aβ-mediated secretion of inflammatory cytokines
and neurotoxicity, decreasing the number of activated micro-
glia and reactive astrocytes (Bishop-Bailey and Warner, 2003;
Heneka et al., 2005). Drug treatment reduces the expression of
the proinflammatory enzymes COX-2, iNOS and beta-
secretase-1 (also called β-site of APP cleaving enzyme,
BACE1) mRNA and protein levels (Heneka et al., 2005). In
addition, PPARγ depletion potentiates beta-secretase mRNA
levels by increasing BACE1 gene promoter activity. Con-
versely, overexpression of PPARγ, as well as NSAIDs and
PPARγ activators, reduced BACE1 gene promoter activity.
These recent results suggest that PPARγ could be a repressor
of BACE1 binding to a peroxisome proliferator responsive
element (PPRE) located in the BACE1 gene promoter. These
effects may explain the overexpression of BACE1 in the brain
under inflammatory conditions and emphasize the hypothesis
that neuroinflammatory mechanisms significantly contribute to
the pathogenesis of AD. This could be a potential mechanism
by which NSAIDs have a protective effect against the
development of AD (Sastre et al., 2006).
Currently, selective COX-2 inhibitors are used more
frequently than the other NSAIDs because they produce the
same pharmacological effects as non-selective COX inhibitors
without the attendant COX-1 inhibition related toxic effects on
stomach lining. Unfortunately, this class of drugs has recently
been shown to increase the risk of cardiovascular events,
resulting in the withdrawal of some of these drugs from the
market and the halting of some clinical trials. Among those
halted, a trial with celecoxib in AD (Couzin, 2004).
Neuroprotective effects of NSAIDs in Parkinson's disease:
experimental evidence
Since the end of the 1980s, when McGeer and colleagues
(McGeer et al., 1988) in their seminal study reported a large
number of reactive leukocyte antigen-DR (HLA-DR)-positive
microglial cells in the SNc and striatum of patients with PD,
several experimental investigations have provided further
plausible evidence for the activation of a proinflammatory
response in this disease (Mogi et al., 1994a,b; Mogi et al., 1995;
Blum-Degen et al., 1995; Rowe et al., 1998; Langston et al.,
1999; Mirza et al., 2000; Knott et al., 2000, 2002; McGeer et al.,
2002; Imamura et al., 2003; Ouchi et al., 2005; Ishida et al.,
2006). The importance of the subject, has engaged several
groups in the emerging and promising theme of NSAIDs and
neurodegeneration. As far as we are aware, nineteen studies
have been carried out in which the effects of NSAIDs have been
tested on animal (mouse and rat) models of PD and cell cultures
(Table 3). This evidence supports the use of NSAIDs in
reducing the pathological burden of the disease; ASA was the
most tested drug (8 studies), followed by its metabolite SA (5
studies), only 1 studied the effect of COX-1 but 10 focused on
Table 3
Experimental studies with NSAIDs
Study Experimental model NSAIDs Outcome
Grilli et al., 1996 Primary cultures of rat cerebellar granule
cells and hippocampal slices
ASA (1, 3 mM) Protection ↓NF-κB
SA (3,10 mM) Protection ↓NF-κB
indomethacin (1–20 μM) NO protection
Aubin et al., 1998 MPTP mouse model of PD, MPTP
(15 mg/kg, s.c.)
ASA (100 mg/kg) Protection ROS scavenging
Aspegic (200 mg/kg) Protection ROS scavenging
SA (100 mg/kg) Protection ROS scavenging
Paracetamol (100 mg/kg) NO protection
Diclofenac (100 mg/kg) NO protection
Ibuprofen (20 mg/kg) NO protection
Indomethacin (100 mg/kg) NO protection
Ferger et al., 1999 MPTP mouse (C57BL/6) model of PD,
MPTP 30 mg/kg or 40 mg/kg s.c.
SA (50 mg/kg or 100 mg/kg i.p.) Protection ROS scavenging
Mohanakumar et al., 2000 MPTP mouse model of PD, MPTP
(30 mg/kg i.p. twice, 16 h apart).
SA (25–100 mg/kg, i.p.) Protection ROS scavenging
↓akinesia or catalepsy
Casper et al., 2000 Cultured primary rat embryonic neurons
from mesencephalon GLU-toxicity
ASA (1 mM) Protection mechanism??
Paracetamol (1 mM) Protection mechanism??
Ibuprofen (0.1 mM) Protection mechanism??
Teismann and Ferger, 2001 MPTP mouse (C57BL/6) model of PD,
MPTP (30 mg/kg s.c.)
ASA (10, 50, 100 mg/kg i.p.) Protection ↓COX-1/COX-2
↓akinesia or catalepsyMeloxicam (2, 7.5, 50 mg/kg i.p.)
Protection ↓COX-2 ↓akinesia or
catalepsy
Carrasco and Werner, 2002 Cultured primary rat embryonic neurons
from mesencephalon
6-OHDA (1.25–25 μM) ASA (1 mM) Protection mechanism??
MPP+ (0.625–20 μM) ASA (1 mM) Protection mechanism??
Kurkowska-Jastrzębska
et al., 2002
MPTP mouse model of PD Indomethacin (1 mg/kg, i.p.) Protection ↓ inflammation
Sairam et al., 2003 MPP+ rat model of PD, intrastriatal 100 nmol
(in 4 μl/animal)
SA (50 and 100 mg/kg, i.p.), Protection ROS scavenging
diclofenac (5–100 mg/kg, i.p.) NO protection
celecoxib (2.5–50 mg/kg, i.p.) NO protection
Teismann et al., 2003 MPTP mouse (C57/BL/6) model of PD,
MPTP (20 mg/kg i.p. four injections)
Rofecoxib (12.5–50 mg/kg,
i.p. for 5 days before and after
Protection ↓COX-2
Klivenyi et al., 2003 MPTP mouse (C57/BL/6) model of PD,
MPTP (20 mg/kg i.p)
Rofecoxib Protection ↓COX-2
Przybyłkowski et al., 2004 MPTP mouse (C57/BL/6) model of PD,
MPTP (60 mg/kg i.p)
Rofecoxib (10 mg/kg, i.p., for 21
days 1 day after the injury MPTP)
NO protection
Maharaj et al., 2004 MPP+ rat model of PD, intrastriatal
(32 nmol in 1 μl)
ASA (100 mg/kg, i.p. four
injections, after MPP+ infusion)
Protection ROS scavenging
Paracetamol (100 mg/kg, , i.p. four
injections, after MPP+ infusion)
Partial protection ROS
scavenging
Carrasco et al., 2005 Rat mesencephalic neuronal cultures Ibuprofen (25, 100, 250 μM) Protection for both toxins ↓COX-2
6-OHDA (2.5–10 μM) SC-560 (6.5 μM) NO protection
MPP+ (2.5–10 μM) NS-398 (5–50 μM) and Cayman
10404 (0.1–10 nM)
Protection against only
6-OHDA-toxicity ↓COX-2
Sánchez-Pernaute et al., 2004 6-OHDA rat model of PD, intrastriatal
(22.5 μg)
Celocoxib (20 mg/kg i.p.,
−1 up to +12 or 21 days)
Protection ↓COX-2
Morioka et al., 2004 PC12 cells MPP+ (30 μM) Indomethacin (100 μM) Potentiation of neurotoxicity ↓MRP
Ibuprofen (100 μM) Potentiation of neurotoxicity ↓MRP
Ketoprofen (100 μM) Potentiation of neurotoxicity ↓MRP
Diclofenac (100 μM) Potentiation of neurotoxicity ↓MRP
ASA (100 μM) No effect
Wang et al., 2005 Primary mesencephalic mixed
neuron-microglia cultures
DuP697 (10 nM) Protection ↓COX-2
MPP+ (0.5 μM)
Di Matteo et al., 2006a,b Rat model of PD, intrastriatal MPP+ or
6-OHDA 1 mM (10 min 1 μl/min)
ASA (100 mg/kg i.p.) Protection for both toxins ROS
scavenging
Meloxicam (50 mg/kg i.p.) NO protection both toxins
Maharaj et al., 2006 Rat model of PD, intranigral 1 mM
(32 nmol in 1 μl)
ASA (100 mg/kg i.p.) Protection ROS scavenging and
↓superoxide anion generationParacetamol (100 mg/kg i.p.)
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the enzyme. The results of 10 years of research will be reported
chronologically.
The first piece of experimental evidence in the field was
published by Grilli and co-workers a few years after the McGeer
study (Grilli et al., 1996). These authors showed that ASA and
its metabolite SA, at concentrations compatible with amounts in
plasma during treatment of chronic inflammatory states, were
protective against neurotoxicity elicited by GLU in primary
cultures of rat cerebellar granule cells and hippocampal slices.
Indomethacin, however, was unable to prevent GLU-induced
cell death. The common molecular target for ASA and SA but
not for indomethacin was identified as COX-independent and
involved specific inhibition of GLU-mediated induction of NF-
κB, suggesting, for the first time, a link between neuroprotec-
tion and the nuclear event (Grilli et al., 1996).
Moreover, Aubin and colleagues (1998) confirmed these
ASA neuroprotective effects in a low dosage MPTP mouse
model of PD. In accordance with the previous study, using an ex
vivo and in vitro approach they found that the protective effect
of ASA, its soluble lysine salt (Aspegic) and SA, is probably not
due to COX inhibition. Their assertion was just a speculation
based on the fact that other COX inhibitors such as paracetamol,
diclofenac and indomethacin were ineffective. Likewise, the
involvement of NF-κB was ruled out based on the lack of effect
of dexamethasone, a glucocorticoid known to powerfully
repress this nuclear factor function. ROS scavenging activity
as a possible mechanism for explaining SA and ASA's
neuroprotection was instead proposed by these authors (Aubin
et al., 1998).
In addition, SAwas found to be neuroprotective, even if not
completely, in a higher dosage MPTP mouse model of PD
(Ferger et al., 1999). SA acted on both the terminal and cell
body area of the nigrostriatal system as might be deduced by the
pronounced effect against both MPTP-induced striatal DA
depletion and loss of tyrosine hydroxylase (TH) immunoreac-
tive on nigral cell bodies. Ferger and colleagues in their paper
pointed out that SA neuroprotective properties are based on its
effective hydroxyl radicals scavenger rather than on its COX-
inhibitory action (Ferger et al., 1999).
This piece of evidence has been further confirmed by
Mohanakumar et al. (2000), in a MPTP mouse model of PD,
where SA demonstrated a clear antioxidant action blocking
toxin-induced glutathione (GSH) and DA depletion acting as a
hydroxyl radicals scavenger in the brain and indicates its
strength as a valuable neuroprotectant. SA did not inhibit MAO-
B as has been previously shown by Aubin et al. (1998),
overruling the possibility that its observed neuroprotective
effects were caused by the possible blockade on the production
of MPP+ from MPTP due to the presence of this enzyme in the
brain. It is worth noting that these authors showed for the first
time that SA pre-treatment also significantly improved motor
activity, blocking akinesia or catalepsy caused by MPTP
administration (Mohanakumar et al., 2000).
An in vitro study evaluated the effects of some NSAIDs on
cultured primary rat embryonic neurons from rat embryos
mesencephalon also containing glial cells, an experimentalpreparation that reflects the cellular composition of the brain
well, and is therefore useful in the study of neuroinflammation
(Casper et al., 2000). Incubation with ASA, paracetamol or
ibuprofen protected DAergic neurons against GLU toxicity,
considering as indices the reduction of the decrease in DA
uptake caused by GLU, and the attenuation of the TH-positive
cells loss. Among the NSAIDs tested, ibuprofen was the most
effective and surprisingly increased the number of DA cells in
basal conditionmost likely protecting them from the excitoxicity
associated with culture medium change (Casper et al., 2000).
So far experimental evidence has suggested that NSAIDs act
as neuroprotectants essentially through a nonclassical mechan-
ism. Against the general trend, the role of COX-1 and COX-2
enzymes was reassessed by Teismann and Ferger (2001), who
proposed the use of COX-2 inhibitors as a new non-DAergic
therapy for PD. Their assumption was based on the effects of
ASA and meloxicam, the latter a preferential antagonist for the
COX-2 isoform, in a MPTP mouse model of PD. Both drugs, at
higher dosages, showed an almost complete protection against
MPTP toxicity. ASA and meloxicam antagonized MPTP-
induced striatal DA depletion, attenuated the reduction of TH
immunereactivity of the SNc and the MPTP-induced decrease
in locomotor activity (Teismann and Ferger, 2001).
Carrasco and Werner (2002), using a neuronally enriched
mesencephalic culture system, showed that ASA was also able
to increase the survival of DA neurons exposed to low doses of
6-OHDA and MPP+ but not to counteract the morphological
changes induced by the toxins. However, the authors did not
investigate the possible protective mechanism of ASA (Car-
rasco and Werner, 2002).
The role of COX-activity in the pathogenesis of PD was
studied for the first time by Kurkowska-Jastrzębska et al. (2002)
using indomethacin in a MPTP mouse model of PD. This drug
protected SNc DA neurons against the toxin effect and it was
associated with diminished microglial activation and lympho-
cytic infiltration in the damaged areas. Thus, reduced inflam-
mation by indomethacin might result in less damage to DAergic
neurons. However, in this study, microglial and lymphocytes
accumulation was decreased only in association with less
neuronal impairment, when indomethacin was given before
MPTP. Indomethacin in higher dose or given 24 h after
intoxication did not decrease inflammatory reaction. Therefore,
the anti-inflammatory effect of indomethacin might be second-
ary to the diminished neural injury which probably results from
a direct interaction of indomethacin maybe on neurons
scavenging ROS. However, indomethacin appeared to be toxic
in high doses indicating that doses of NSAIDs should be
considered carefully in clinical trials (Kurkowska-Jastrzłbska
et al., 2002).
In view of conflicting reports so far on the role of the
NSAIDs as neuroprotectants and the involvement of COX
isoenzymes in their effects, Sairam et al. (2003), used SA,
diclofenac and celecoxib in a model of PD induced infusing
MPP+ directly into the striata of rats. These three anti-
inflammatory agents have different mechanisms of action. SA
is well known to have an effect independent of the COX
activity, diclofenac is a non-selective reversible COX-inhibitor
304 E. Esposito et al. / Experimental Neurology 205 (2007) 295–312and celecoxib is instead a specific COX-2 inhibitor. The failure
of celecoxib and diclofenac to protect animals against MPP+-
induced DA depletion, together with a significant attenuation of
severe DA depletion (>65%) induced by SA indicate the
absence of the involvement of prostaglandins (PGs) in MPP+
action. The authors conclude that the difference in neuroprotec-
tion among the NSAIDs used in the study is mostly dependent
on their antioxidant activity (Sairam et al., 2003).
Further insights into the field have been provided by
Teismann and colleagues (2003) in a very elegant in vitro
study from MPTP-treated mice and post-mortem PD samples.
These researchers showed that COX-2 isoenzyme is up-regulated
in the SNc DAergic neurons in both animal and human samples,
COX-2-mediated neurodegeneration might be correlated to its
catalytic activity through the production of prostaglandins and
maybe also to the oxidation of catechols such as DA (Asanuma
and Miyazaki, 2006). Treatment with rofecoxib, before and after
MPTP-injection, blocked the increase of PGE2 in the midbrain,
doubled the number of the surviving TH-positive neurons, and
prevented the rise in protein cysteinyldopamine, an index of DA
quinones production. Surprisingly, neither pharmacological nor
genetic abrogation of COX-2 activity mitigate inflammatory
processes (Teismann et al., 2003).
The neuroprotective effects of rofecoxib have also been
shown by Klivenyi and colleagues (2003) in MPTP model of
PD in mice. They showed that the selective COX-2 inhibitor
either alone or in combination with creatine, that facilitates
metabolic channelling and shows antiapoptotic properties
(Wyss and Kaddurah-Daouk, 2000) protected against striatal
DA depletions and loss of SN TH-immunoreactive neurons.
Administration of rofecoxib with creatine produced significant
additive neuroprotective effects against DA depletions. These
results suggest that a combination of a COX-2 inhibitor with
creatine might be a useful neuroprotective strategy for PD
(Klivenyi et al., 2003).
The work of Przybyłkowski and colleagues (2004) is also
noteworthy, they have shown, in theMPTPmodel of PD inmice,
that rofecoxib has no neuroprotective effect when it is given after
MPTP intoxication, even for a long period, revealing that the
time of COX-2 inhibition is critical to achieve a protective effect.
Consequently, COX-2 activity, prostaglandins production and
oxygen species formation might not play a detrimental role in
neuronal cells death, at least when the injury process has started
already. The inhibition of COX-2 activity could, nevertheless, be
harmful to neurons injured by MPTP. Indeed, the authors
showed that, in later stages of injury, COX-2, through the
formation of cyclopentenone prostaglandins derived from
PGD2, may participate in the resolution of inflammation and
even in the regeneration process (Przybyłkowski et al., 2004).
Maharaj et al. (2004) on the other hand, showed that ASA
given after MPP+ administration, completely blocked MPP+-
induced striatal DA depletion. Similar treatment with paracetamol
resulted instead only in a partial protection. In both experimental
conditions, rat brain homogenates and rats intranigrally treated
with MPP+, ASA and paracetamol acted mainly as antioxidants.
They were also capable of blocking hydroxyl radicals production
and lipid peroxidation in vitro, but in this ASA was the weakercompared to paracetamol. In conclusion, ASA appears to offer
itself as a prophylactic as well as an adjuvant therapy for PD and
its neuroprotective effect is only partially mediated by ROS
scavenging properties (Maharaj et al., 2004).
Sánchez-Pernaute and colleagues (2004) in a 6-OHDA rat
model of PD, showed that selective inhibition of COX-2 by
treatment (pre and post lesion) with celocoxib is protective
against the neurotoxin effect. The authors evaluated celocoxib
effects using micro PET and immunohistochemical techniques,
and observed a decrease in microglial activation in the striatum
and ventral midbrain associated with a prevention of the
progressive degeneration seen in the intrastriatal 6-OHDA
retrograde lesioned rats treated with the vehicle. The benefit of
COX-2 activity inhibition might be attributed to a selective
decrease of the harmful glial cells and to the no effect on the
protective astroglia. Celocoxib's rescue of DA toxin-insulted
neurons from death could be mediated by both neuronal and
glial COX-2, but in any case the effect obtained by this drug is
to create favourable conditions for the prevention of progressive
neurodegenerative cascades during and after neuronal injury
similar to that seen in PD (Sánchez-Pernaute et al., 2004).
Furthermore, results obtained in cultures of embryonic rat
mesencephalic neurons treated with 6-OHDA and MPP+
showed that these two neurotoxins act differently in the killing
of DA neurons, neuronal COX-2 activity and PG production is
involved only in the 6-OHDA-neurotoxic effect whereas MPP+
toxicity does not require COX involvement (Carrasco et al.,
2005). This evidence comes from experiments carried out with
ibuprofen, a non-selective COX inhibitor, SC-560 a COX-1
selective inhibitor and two selective COX-2 inhibitors, NS-398
and Cayman 10404, showing that COX-2, but not COX-1, is
involved in 6-OHDA toxicity. Since ibuprofen attenuated both
6-OHDA and MPP+-neurotoxicity, the authors proposed that
this drug has additional COX-independent effects as yet not
well identified (Carrasco et al., 2005). Some discrepancies with
the previous study have been reported by Wang et al. (2005).
These authors found that MPP+ induces DAergic degeneration
enhancing COX-2 expression in both glial and DA cells in
primary mesencephalic mixed neuron-microglia cultures. Its
toxicity is undoubtedly mediated through PGE2, the levels of
which almost doubled. They observed that the COX-2 specific
inhibitor DuP697, attenuates microgliosis by decreasing PGE2
production, and leads DA neurons to the rescue from a
secondary lethal neurotoxicity attack (Wang et al., 2005).
Valdecoxib, another selective COX-2 inhibitor, acted similarly
in a mouse model of PD abating microglia activation and the
consequential MPTP-induced toxicity, confirming that COX-2
and activated microglia play an important role in secondary
injury of DA neurons. Moreover, these cellular protective
effects of valdecoxib pretreatment were confirmed in the
behavioural counterpart of the experimentation in which it
also alleviated locomotor deficits induced by the toxin, assessed
in open field and vertical activity (Wang et al., 2005).
A recent study threw some light on this question by
confirming that ASA has a protective effect against neuronal
damage induced by intrastriatal infusion of MPP+ and 6-OHDA
using a microdialysis approach in conscious rats (Di Matteo et
Table 4
Epidemiological studies of NSAIDs and PD
Study Duration
NSAIDs use
Overall
cohort
PD
cases
Relative
risk
95% CI
Chen et al., 2003 >14 years 142,902 415 0.55 0.32–0.96
Chen et al., 2005 8 years 146,565 413 0.65 0.48–0.88
Case control >3 years 7896 1258 0.93 0.80–1.08
Hernán et al., 2006 women 493 1.21 0.95–1.54
men 765 0.79 0.65–0.96
Bower et al., 2006 20 years 404 202 0.50 0.20–1.5
Ton et al., 2006 20 years 589 206 0.90 0.59–1.35
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neuroprotective effect was evidenced in vivo, indeed, this has
been observed only under in vitro and ex vivo conditions to date.
Pre-treatment of rats with ASA, protected DA neurons in both
animal models (MPP+ and 6-OHDA-lesioned) as indicated by
electrochemical and TH immunostaining evidence, whereas
meloxicam, a selective COX-2 inhibitor, was devoid of any
activity. The authors have confirmed these findings also in vitro,
in a human neuroblastoma cell culture line. In fact, ASA, but not
meloxicam, inhibited cell death induced by treatment with
MPP+, in a dose-dependent manner (unpublished observation).
The mechanism of action of ASA seemed to be different in each
model since it was associated with ROS scavenging activity in
the 6-OHDAmodel, but not in theMPP+ model that surprisingly
did not induce any hydroxyl radicals formation at the
concentration used in this study. Therefore, it is likely that the
protective effect exerted by ASA, in vivo, may be due to
inhibition ofMPP+ toxicity at the cell level, possibly by blocking
NF-κB or caspase activation, providing further evidence that the
neuroprotective effect of NSAIDs might be independent from
COX-2 inhibition. Other mechanisms, such as hydroxyl radicals
scavenging activity, as in the model of 6-OHDA-induced
damage, cannot be ruled out however. (Di Matteo et al., 2006a).
Finally, Maharaj et al. (2006) have provided novel informa-
tion by highlighting the role of NSAID agents on a different
molecular target, the mitochondrion. These authors studied the
effect of MPP+ on striatal mitochondrial function and the ability
of MPP+ to generate superoxide hydroxyl radicals and the effect
of ASA and paracetamol. These NSAIDs prevented MPP+-
induced inhibition of the mitochondrial electron transport chain
and complex I activity. Also, ASA and paracetamol signifi-
cantly attenuated MPP+-induced superoxide anion generation.
The results of this study suggest that these NSAIDs not only
serve as hydroxyl radicals scavengers but also prevent
mitochondrial dysfunction and subsequent superoxide anion
generation (Maharaj et al., 2006).
Conversely, Morioka et al. (2004), have shown that treatment
with some NSAIDs might instead aggravate the neurodegen-
erative processes. They reported that coincubation of PC12 cells
with indomethacin, ibuprofen, ketoprofen, or diclofenac,
markedly enhanced MPP+-induced cell death. This additive
detrimental effect was not observed after treatment with ASA
and NS-398, a COX-2 selective inhibitor, that had no effects on
the toxin action. The authors showed that the potentiating effect
of some NSAIDs on MPP+-induced cell death was not
associated with any of the classical and non, actions attributed
to them so far (i.e., inhibition of COX enzymes, ROS
scavenging, antagonism at PPARγ, caspase-3-apoptotic cell
death pathway). The possible mechanism whereby NSAIDs
potentate MPP+-induced cell death might be the increase of
intracellular accumulation of MPP+. These drugs actually
suppressed the cellular efflux of MPP+ by the blockade of
multidrug resistance proteins (MRP) (Morioka et al., 2004).
The use of different experimental conditions (i.e., in vivo
versus in vitro, ex vivo, species or strain of animal used, cell
types) drugs (NSAIDs are a heterogeneous chemical group also
with different potency in crossing the blood–brain barrier),therapy duration (i.e., pre-treatment versus post-treatment or
combination of both), time of observation, dose and type of
neurotoxins used, may explain the differences among the
studies here reviewed and, sometimes, the conflicting results.
Overall, there is no doubt that ASA, SA, ibuprofen and
especially COX-2 selective inhibitors exert neuroprotective
effects, although the mechanism through which they act still
remains controversial. Hitherto, the involvement of classical
versus non-classical mechanisms in the beneficial effects of
NSAIDs remains to be fully unravelled. However, their broad
sites of action and pharmacological effects (from anticancer to
antipyretic) might be the basis on which their efficacy in
neurodegenerative disease is founded.
Neuroprotective effects of NSAIDs in Parkinson's disease:
epidemiological evidence
Despite the evidence of inflammation in the brains of
patients with PD, confirmed successively in animal models of
PD, since the mid 1990s, NSAIDs have not yet been formally
tested in PD. To date, only five epidemiological studies have
been carried out analyzing the association between regular use
of NSAIDs and the risk of PD with conflicting results (Table 4).
The first piece of evidence was provided by Chen et al.
(2003) from the Harvard School of Public Health. They
published the first study investigating prospectively the
potential benefit in humans of the use of NSAIDs in reducing
the risk of PD. These researchers found that regular users of
these drugs had a lower risk of PD than non-users. The study
was conducted among participants in the Health Professionals
Follow-Up Study and the Brigham and Women's Hospital
based Nurses Health Study who were free of PD, stroke or
cancer at the start of the research. More than 44,000 men and
nearly 99,000 women were followed for 14 years and 18 years,
respectively. Use of ASA and non-ASA NSAIDs (such as,
diflunisal, ibuprofen, indomethacin, naproxen) was assessed via
biennial questionnaires. A total of 236 men and 179 women
developed PD during the course of the study. The risk of
developing PD was 45% lower among regular users of non-
ASA NSAIDs compared to non-users (pooled multivariate
relative risk (RR), 0.55; 95% confidence interval (CI), 0.32–
0.96). Regular use of non-ASA NSAIDs was reported by 6.1%
of the men at the beginning of the study and 3.7% of the women.
A similar decrease in risk was also found among participants
who took two or more tablets of ASA per day compared to non-
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among those who took smaller amounts of ASA per day or
paracetamol. Additionally, increasing benefits were observed
with longer duration of use of non-ASA NSAIDs (Chen et al.,
2003). It is worth noting, that the Chen study may underestimate
the protective effect of NSAIDs, since PD is much more
common in people over 75 years old, an age group not included
in the Chen team's data. Therefore, benefits of even greater
magnitude might be demonstrable if this intervention were
applied to the same population as it aged beyond 75 years.
These data, however, provide little support for the routine use of
NSAIDs as disease-modifying agents in PD, since to prevent
one additional case of PD 98 individuals would have to be
treated with them (Schiess, 2003).
A subsequent prospective study conducted by the same
group has provided further insights (Chen et al., 2005). Chen
and co investigators continued examining the relationship
between NSAIDs use and risk of PD this time, utilizing another
large cohort, the American Cancer Society's Cancer Prevention
Study II Nutrition Cohort of 146,565 people. Between 1992 and
2000 they recorded 413 new cases of PD in the cohort.
Ibuprofen was associated with 35% lower risk of PD (RR, 0.65;
CI 95% 0.48–0.88), with similar risk reductions for men and
women regardless of age or smoking status. There was a
significant trend for lower risk with increasing consumption of
ibuprofen (from RR 0.73 with fewer than 2 tablets per week to
RR 0.61 for daily use) but duration of use made little difference.
In contrast to the previous study, no significant associations
were found for ASA, other NSAIDs or paracetamol (Chen et al.,
2005). These discrepancies might be simply explained by the
fact that considerably more people in the cohort used ibuprofen
than other medications. However, the authors also did not
exclude that there may be an ibuprofen-specific effect against
PD, related to its unique molecule. Another limitation of this
study is that because ibuprofen is an over-the-counter medica-
tion, the so-called nonusers could have taken ibuprofen years
ago, consequently, a short-term clinical study might not give
complete data. Long-term data would be necessary to more fully
discern users and nonusers.
Recently, another group from the Harvard School of Public
Health has conducted a case-control study on subjects with no
history of PD or parkinsonism-related drug use at baseline
(Hernán et al., 2006). Their study was nested within a cohort of
the world's largest computerised database, the British General
Practice Research Database (GPRD). The authors analyzed
1,258 PD cases and 6,638 controls, and reported a surprising
finding: nonASA NSAIDs use reduces PD risk only in men but
not in women. Use of nonASA NSAIDs was associated with a
20% reduction in the incidence of PD among men (odds ratio
(OR), 0.79; CI 95% 0.65–0.96), and a 20% increase in the
incidence of PD among women (OR, 1.21; CI 95% 0.95–1.54)
(Hernán et al., 2006). Although sex differences in PD risk have
been previously reported for caffeine consumption (Ascherio
et al., 2001) and alcoholism (Hernán et al., 2004), this was an
unexpected finding that warrants further research.
Less promising insights have been provided by Bower and
colleagues (2006) from the Mayo Clinic College of Medicine inRochester, Minnesota. They explored the association of PD
with the use of NSAIDs in a population-based, case-control
study for a total of 392 individuals. The investigators used the
medical records linkage system of the Rochester Epidemiology
Project to identify 196 subjects who developed PD from 1976 to
1995. Consistent with the previous epidemiological studies
(Chen et al., 2003, 2005; Hernán et al., 2006), Bower and
colleagues found that cases of PD used NSAIDs (excluding
ASA) less frequently than controls (OR 0.5; CI 95% 0.2–1.5);
however, the difference did not reach significance. This trend
finding was similar for both NSAIDs and steroidal agents
considered separately. The use of ASA was not significantly
associated with PD as shown previously (Chen et al., 2005;
Hernán et al., 2006). These investigators also showed a
significant association between pre-existing immune-mediated
diseases and the later development of PD (OR 1.8; 95% CI:
1.1–3.1). The association was stronger for women and for
earlier onset of PD cases, but neither of these differences
reached significance. These results support the hypothesis that
there is an inflammatory component in the pathogenesis of PD
and provide a rationale for the use of NSAIDs as neuroprotec-
tants capable of delaying onset or slowing progression of the
disease (Bower et al., 2006). Since patients with diseases of
immediate-type hypersensitivity are genetically predisposed to
initiate a humoral response to low levels of antigens, they might
also be predisposed to initiate neuroinflammatory responses as
well and play a role in the aetiology of PD (McGeer and
McGeer, 1997).
The latest available data on the subject come from Ton and
colleagues (2006) from the University of Washington and,
unfortunately, they have continued in dampening the initial
enthusiasm. In an American population-based case-control
study these investigators did not observe a significant associa-
tion between PD and NSAIDs. Subjects among enrollees of a
health maintenance organization included 206 cases between
ages 35 and 89 with a new diagnosis of idiopathic PD between
1992 and 2002, and 383 randomly selected controls. Exposure
to NSAIDs was ascertained from an automated pharmacy
database. After adjusting for age, sex, smoking, duration of
enrolment, and clinic, the risk of PD among individuals who
received non-ASA NSAIDs between 1977 and 1992 was 0.90
(95% CI: 0.59–1.35) and 1.67 (95% CI: 0.60–4.60) between
1993 and 2002. Use of ibuprofen was not associated with PD
(OR: 0.89; 95% CI: 0.60–1.32). The risk of PD associated with
ASA or ASA-containing medications was 0.74 (95% CI: 0.49–
1.12). These results provide only limited support for the
hypothesis that use of ASA may reduce the risk of this disease,
but this association was statistically imprecise and no clear trend
according to number of ASA prescription was observed. In
addition, no indication at all of protection from other NSAIDs
was revealed (Ton et al., 2006).
Differences in the methods of ascertaining medication
exposures, in the extent or timing of exposure to NSAIDs, as
well as chance, may account for the discrepant findings from
this and the earlier studies. These findings offer, at most, a
limited support for the hypothesis of neuroprotection from
ASA, and no indication of protection from other NSAIDs.
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counter medication use will clarify these associations. Indeed,
these unclear indications must be clarified and corroborated by
clinical trial before any firm conclusions can be drawn. In
addition, the role of selective COX-2 inhibitors might be
investigated since only the effect of traditional NSAIDs has
been analyzed by epidemiological studies. Selective COX-2
inhibitors have not been in use long enough for epidemiological
data to be collected. The side effects of NSAIDs therapy, such as
gastrointestinal lesions and cardiovascular risks should also be
carefully evaluated.
Conclusions and implications
From the large amount of literature here reviewed it appears
evident that inflammatory processes are involved in the
pathophysiology of PD. Neuroinflammation, a processes orche-
strated by activated resident microglia cells and sustained by them
and other immune cells, might be contributing to the demise of
nigral DA cells, perpetuating the neurodegenerative phenom-
enon. A large body of information on the molecular and cellular
mechanisms whereby inflammation might induce neuronal death
has been generated in the past few years by researchers in the
neuroscience community. Nevertheless, further clarification of
the role of inflammation in the pathophysiology of basal ganglia
disorders is required, since the overall picture is still confusing.
Complicating the situation is the fact that inflammation is a
double-edged sword and probably starts as a beneficial defence
mechanism that at some point evolves into a destructive and
uncontrollable chronic reaction. Thus, the ideal approach would
be to inhibit the deleterious effects associated with neuroin-
flammationwhile preserving the inflammatory pathways that lead
to neuroprotection. From the above discussion it seems clear that
drugs inhibiting inflammation and microglial activation might be
an important feature of the treatment of PD and also the dementia,
often associated with the disease (Gao et al., 2003; McGeer and
McGeer, 2004; Marchetti and Abbracchio, 2005;McCarty, 2006;
Prodan et al., 2006). Consequently, a rational use of NSAIDs
could be useful as a therapeutic intervention in PD and in other
major neurological diseases with similar etiopathology, such as
AD, ASL and MS. Despite the fact that experimental and
epidemiological evidence has been provided for future use of anti-
inflammation agents, they have not been rigorously corroborated
in trial studies for the treatment of motor disorders as yet andmost
of the data have yielded contradictory results. This may be a result
of the peculiar characteristics of these drugs, so different both at
the chemical and action level. In fact, NSAIDs might exert their
neuroprotective actions not only inhibiting COX enzymes but
also by acting on NF-κB, iNOS, PPARγ, suppressing the
formation of DA quinones, scavenging ROS and RNS activity
and probably by other unknown mechanisms. Indeed, recently it
has also been proposed that anti-inflammatory compounds might
act inhibiting microglial proliferation, modulating the cell cycle
progression and apoptosis (Elsisi et al., 2005).
NSAIDs are sui generis, and the further anti-inflammatory
agents research progresses, the greater the number of indications
that are discovered. NSAIDs have carved out a unique career insuch diverse fields as the treatment of pain, migraine, prevention
of cardiovascular disorders, and the chemoprophylaxis of various
types of cancer. Probably, we are on the threshold of a new
promising career for NSAIDs especially in prevention of
neurodegenerative disease rather than for their treatment. Indeed,
it is quite possible that NSAIDs are ineffective once the
pathological process has started, the pharmacological interven-
tion should start very early in the pre-symptomatic period,
according to some experimental a epidemiological evidence
(Chen et al., 2003; Przyby3kowski et al., 2004; Chen et al., 2005;
Hernán et al., 2006). This need is also corroborated by the recent
failure of some promising clinical trials in AD (Salpeter et al.,
2006; Firuzi and Pratico, 2006) shedding some doubts on the
inflammation hypothesis of AD. Thus, the attractive thesis that
NSAIDs might protect the remaining surviving DA neurons from
the degeneration process and thus slow the ratio of progression of
the illness sounds less promising. Due to the complexity of the
disease, it is possible that combination therapy, concomitant use
of agents with nonoverlapping or even synergistic mechanisms of
action, may represent the best means available to enhance
treatment effectiveness. Some results could be achieved, there-
fore, by combining NSAIDs with other rescue agents, such as
MAO inhibitors (rasagiline, safinamide); mitochondrial function
enhancers (coenzyme Q10, creatine); antiapoptotic agents;
protein aggregation inhibitors and neurotrophic factors (Bonuc-
celli and Del Dotto, 2006). Although this hypothesis is worthy of
consideration, it remains largely undocumented and certainly
deserves further discussion. Furthermore, NSAIDs might be a
beneficial adjuvant to L-DOPA therapy counteracting the toxicity
induced by its long-term use, through anti-inflammatory action
and the reduction of DA quinones generated by L-DOPA therapy
itself (Asanuma and Miyazaki, 2006).
There are also many avenues that remain unexplored, so there
are undoubtedly further advances to be made especially on the
non-classical mechanisms of action of NSAIDs that might lead
us towards a better knowledge of the neuropathological process.
In the next few years, we believe that novel approaches (Di
Giovanni et al., 2006; Schapira et al., 2006) will support the
current dopamine-replacement therapy for PD. Furthermore,
early diagnosis, early symptomatic treatment and particularly the
introduction of neuroprotective therapies will improve PD
pharmacological management, as disease modification remains
the most important goal in PD. Compounds inhibiting neuroin-
flammation such as NSAIDs represent an important starting
point that could, for the first time, lead us to the identification of
disease-modifying agents for this devastating disease.
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